News >

Emerging Approaches Offer Hope in Heavily Pretreated Myeloma

Brandon Scalea
Published: Monday, Aug 06, 2018

Suman Kambhampati, MD

Suman Kambhampati, MD
When patients with multiple myeloma become refractory to lenalidomide (Revlimid) or bortezomib (Velcade), or have penta-refractory disease, there have been limited options left for treatment, according to Suman Kambhampati, MD. Recent studies presented at the 2018 ASCO Annual Meeting indicate that meaningful changes may be on the horizon.

State of the Science Summit, A Summer of Progress: Updates from ASCO 2018, Kambhampati, the co-medical director of the Blood Cancer Program at Sarah Cannon Research Institute, highlighted some of the latest developments in the treatment of patients with relapsed/refractory multiple myeloma.

OncLive: Please provide some background to your presentation on multiple myeloma.

Kambhampati: For myeloma, the theme here, or the big unmet need, is how to treat patients who have lenalidomide- or bortezomib-refractory disease. Also, we struggle with disease that becomes refractory to all agents, which is something we call penta-refractory disease. At the 2018 ASCO Annual Meeting, we saw tremendous data with the bb2121 CAR T cells, showing that patients can achieve progression-free survival of approximately 1 year. What we are seeing is the impact of CAR T-cell therapy in immunotherapy in myeloma.
... to read the full story
To Read the Full Story



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x